A large number of clinical trials have shown stem cell therapy to be a promising therapeutic
approach for the treatment of cardiovascular diseases. Since the first transplantation into …

In primary prevention, regular physical activity decreases the incidence of cardiovascular
disease. At the endothelial level, this decreased incidence was attributed to higher …

Endothelial progenitor cells (EPCs) have been isolated and shown to be effective in animal
models of ischemia, and many groups involved in clinical trials have demonstrated that EPC …

Rationale: A growing number of patients with coronary disease have refractory angina.
Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous …

Cardiovascular regenerative therapies are pursued on both basic and translational levels.
Although efficacy and value of cell therapy for myocardial regeneration can be debated …

Background—A growing population of patients with coronary artery disease experiences
angina that is not amenable to revascularization and is refractory to medical therapy …

OBJECTIVES: Cell therapy may offer novel therapeutic options for chronic ischemic heart
disease. In a clinical trial, we first assessed the feasibility and safety of intramyocardial …

Background—We compared the therapeutic potential of purified mobilized human CD34+
cells with that of mobilized total mononuclear cells (tMNCs) for the preservation/recovery of …

Background—Intracoronary administration of autologous bone marrow–derived
mononuclear cells (BM-MNC) may improve remodeling of the left ventricle (LV) after acute …

A number of preclinical studies have indicated the therapeutic potential of endothelial
progenitor cells for vascular regeneration in ischemic diseases. A phase I/IIa clinical trial of …